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Abstract
Efficient vaccination against the parasite Leishmania major, the causative agent of human cutaneous leishmaniasis, requires
development of type 1 T-helper (Th1) CD4+ T cell immunity. Because of their unique capacity to initiate and modulate
immune responses, dendritic cells (DCs) are attractive targets for development of novel vaccines. In this study, for the first
time, we investigated the capacity of a DC-targeted vaccine to induce protective responses against L. major. To this end, we
genetically engineered the N-terminal portion of the stress-inducible 1 protein of L. major (LmSTI1a) into anti-DEC205/
CD205 (DEC) monoclonal antibody (mAb) and thereby delivered the conjugated protein to DEC+ DCs in situ in the intact
animal. Delivery of LmSTI1a to adjuvant-matured DCs increased the frequency of antigen-specific CD4+ T cells producing
IFN-c+, IL-2+, and TNF-a+ in two different strains of mice (C57BL/6 and Balb/c), while such responses were not observed with
the same doses of a control Ig-LmSTI1a mAb without receptor affinity or with non-targeted LmSTI1a protein. Using a
peptide library for LmSTI1a, we identified at least two distinct CD4+ T cell mimetopes in each MHC class II haplotype,
consistent with the induction of broad immunity. When we compared T cell immune responses generated after targeting
DCs with LmSTI1a or other L. major antigens, including LACK (Leishmania receptor for activated C kinase) and LeIF
(Leishmania eukaryotic ribosomal elongation and initiation factor 4a), we found that LmSTI1a was superior for generation of
IFN-c-producing CD4+ T cells, which correlated with higher protection of susceptible Balb/c mice to a challenge with L.
major. For the first time, this study demonstrates the potential of a DC-targeted vaccine as a novel approach for cutaneous
leishmaniasis, an increasing public health concern that has no currently available effective treatment.
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Introduction
Leishmaniases are a spectrum of diseases caused by different
species of Leishmania spp. parasites, with clinical presentation
ranging from a fatal visceral form (L. donovani) to a localized self-
healing cutaneous lesion (L. major) [1]. In humans, acquired
resistance to L. major infection is primarily mediated by cellular
immunity, particularly antigen-specific Th1 CD4+ T cells [2].
Similarly, Th1-dependent protection is observed in mouse
experimental models of L. major infection [3]. Resistant strains,
such as C57BL/6, develop Th1 immune responses producing high
levels of gamma interferon (IFN-c), resulting in self-healing [3,4,5].
In contrast, Balb/c mice develop a typical Th2 response
producing high amounts of IL-4, which is accompanied by disease
progression after infection [6]. In susceptible Balb/c mice,
protective Th1 T cell responses can be promoted by immunization
[7,8,9,10,11,12], suggesting that vaccines capable of generating
potent and broad Th1 T cell responses can provide protective
immunity to Leishmania infection. However, despite current
evaluation of several strategies as potential candidates, there is
no licensed vaccine available against Leishmania [13].
Dendritic cells (DCs) are highly specialized antigen-presenting
cells essential for generation of protective T cell immune responses
[14,15]. Depending on the nature of the microbial stimulus, they
can direct the development of polarized Th responses [16]. Thus,
manipulation of the DC compartment for generation of antigen-
specific Th1 T cell responses offers a promising strategy for
vaccination against Leishmania. Accordingly, infusion of susceptible
Balb/c mice with DCs loaded ex vivo with L. major antigens induces
protective Th1 T cell responses [7,17,18,19]. An alternative
approach in the intact animal is the use of monoclonal antibodies
(mAbs) against surface uptake receptors to deliver specific antigens
to DCs in situ, within lymphoid tissues. Delivery of vaccine proteins
within mAbs increases the efficiency of antigen presentation on
MHC class II complexes by approximately 100-fold
[20,21,22,23,24]. Importantly, DCs targeted with anti-receptor
mAbs can induce protective Th1 CD4+ T cell responses when an
appropriate adjuvant is coadministered [24,25,26]. In particular,
we have shown that the synthetic form of viral double-stranded
RNA, polyinosinic:polycytidylic acid (poly IC), and its more
RNase-resistant analog stabilized with poly-L-lysine, poly ICLC,
are superior adjuvants for generation of Th1 T cell responses
induced by DC-targeted vaccines [26]. Hence, delivery of viral or
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bacterial antigens to DCs using fusion mAbs against DEC205/
CD205 (DEC) coadministered with poly IC or poly ICLC results
in Th1 CD4+ T cell responses that protect mice against
recombinant vaccinia virus expressing gag-p24 or the bacterium
Yersinia pestis, respectively [22,25,27,28].
In the present study, we, for the first time, examined the
potential of targeting DCs in vivo for induction of protective Th1 T
cell immune responses against the parasite L. major. We initially
focused our DC-targeting approach to the stress-inducible 1
antigen, an intracellular protein of L. major (LmSTl1) [29].
Evidence suggesting LmSTI1 is a good candidate for a protective
vaccine includes the following: First, LmSTI1-specific Th1 T cells
are found in draining lymph nodes of L. major-infected Balb/c mice
[30]; second, high doses of soluble LmSTI1 protein or LmSTI1-
encoding DNA, coadministered with IL-12, induce protection
against L. major infection [31]; and third, Leish-111f (or LEISH-
F1), a single recombinant poly-protein containing LmSTI1,
induces Th1 T cell responses when administered with monopho-
sphoryl lipid A (MPL) [32,33] and has been recently shown to be
safe and well tolerated in human subjects [34]. Our results
demonstrated that delivery of the N-terminal domain of LmSTI1
to DCs in combination with DC maturation stimuli induced
potent and broad antigen-specific CD4+ T cell responses and was
able to protect susceptible Balb/c mice against a subsequent
challenge with L. major. When we compared immune responses
and protection induced by targeting LmSTI1 to DCs with the
delivery of other Leishmania antigens, including LACK and LeIF,
we found that LmSTI1a was superior for generation of IFN-c-
producing CD4+ T cells, which correlated with higher protection
against a L. major challenge. Taken together, our study describes a
novel strategy to induce consistent and highly effective immunity
to the intracellular pathogen L. major and thus provides a
promising new tool for a DC-based vaccine.
Results
LmSTI1, an Antigenic Protein Conserved between
Species of Leishmania, can be Introduced into Anti-
mouse DEC mAb
Th1 immune responses play a critical role in controlling
leishmaniasis, and thus, antigens presented to T cells in MHC class
II complexes have been considered good candidates for vaccines.
An ideal vaccine antigen against Leishmania is expected to be
conserved across different parasite species. Accordingly, the amino
acid sequence of STI1 from L. major (LmSTI1) is .90% conserved
with the STI1 sequence in L. braziliensis, L. infantum, and L. donovani
(Figure S1), causative agents of mucocutaneous or visceral
leishmaniasis, respectively. Furthermore, LmSTI1 lacks homology
with mammalian proteins (not shown), which is desirable for a
vaccine antigen to prevent unwanted autoimmune responses.
The LmSTI1 protein was initially cloned in frame into the
heavy chain of anti-mouse DEC mAb; however, it was highly
unstable and poorly expressed. Therefore, LmSTI1 was cleaved
using an internal NotI site to yield a larger N-terminal portion (aa
1–398, LmSTI1a) and a smaller C-terminal portion (aa 401–546,
LmSTI1b) (Figure S2A), which were both cloned in frame into
anti-mouse DEC mAb and a control Ig mAb that has no receptor
affinity (Figure S2B). The fusion mAbs were successfully expressed
in 293T cells and purified in protein G columns. Because of the
insertion of LmSTI1a or LmSTI1b, the heavy chain of the fused
mAb was approximately 100 or 70 kDa, respectively, as shown by
Coomassie blue staining (Figure S2C) and Western blotting
(Figure S2D). Importantly, fusion of LmSTI1a or LmSTI1b into
anti-DEC mAbs did not disrupt antibody function, as both anti-
DEC-LmSTI1a and anti-DEC-LmSTI1b mAb efficiently bound
to their corresponding receptor on stably transfected CHO cells
but not to nontransfected CHO NEO cells (Figure S2E). Thus,
anti-DEC mAb can be successfully engineered to express the
LmSTI1 antigen from L. major. For our initial characterization of
immune responses, LmSTI1a (N-terminal domain) was used,
given that it covers approximately 72% of the native protein.
Anti-DEC-LmSTI1a mAb Administered with a DC
Maturation Stimulus Induces Multifunctional Th1 CD4+ T
cells
To determine T cell responses induced by LmSTI1a targeted to
DCs via anti-DEC mAb, we inoculated C57BL/6 mice (H-2b)
with 1 mg of mAb along with 50 mg poly ICLC and 25 mg anti-
CD40 mAb (Adjuvant, Adj) as a DC maturation stimulus [22,24].
As a control, we used Ig-LmSTI1a mAb with no receptor affinity.
Two weeks after immunization, antigen-specific immune responses
were evaluated by measuring IFN-c-production in response to a
reactive LmSTI1a peptide mix by multicolor flow cytometry. As
shown in Figure 1A and quantified in Figure 1B, delivery of
LmSTI1a within DEC mAb induced IFN-c-producing CD4+ T
cells. The frequency of the IFN-c+ CD4+ T cells was greater when
LmSTI1a was delivered using anti-DEC mAb compared with
control Ig-LmSTI1a mAbs (Figure 1, A and B). These CD4+ T
cells were antigen-specific since they only produced IFN-c in
response to LmSTI1a reactive peptide mix but not in response to a
negative control LeIF peptide mix (Figure 1, A and B).
Previous studies revealed that protection against L. major
infection in mice [35] and healing of cutaneous leishmaniasis in
humans [36] correlates with the priming of multifunctional Th1
CD4+ T cells that simultaneously secrete high amounts of IFN-c,
IL-2, and TNF-a. Thus, we examined the capacity of LmSTI1a-
specific IFN-c+ CD4+ T cells to produce other cytokines.
Following immunization with anti-DEC-LmSTI1a mAb, approx-
imately 70% of the IFN-c-producing CD4+ T cells, accounting for
approximately 2–3% of the total CD4+ cells, also produced IL-2
and TNF-a (Figure 1C). Furthermore, CD4+ T cells producing
three cytokines, i.e., IFN-c, IL-2, and TNF-a, had the highest
median fluorescence intensity (MFI) for IFN-c compared with T
cells producing only 1–2 cytokine (Figure 1D). This last parameter
has also been associated with protective immunity to Leishmania
infection [35,36].
We then performed similar experiments in susceptible Balb/c
(H-2d) mice, which typically develop a Th2 response to L. major
infection. Anti-DEC-LmsTI1a mAb induced significantly higher
percentage of antigen-specific IFN-c-producing CD4+ T cells than
control Ig-LmSTI1a mAb (Figure 1E), and the majority of these
IFN-c+ CD4+ T cells also produced TNF-a and IL-2 (Figure S3).
Moreover, CD4+ T cells from mice immunized with anti-DEC-
LmSTI1a mAb proliferated vigorously in vitro in response to the
reactive LmSTI1a peptide mix and were able to produce higher
amounts of IFN-c after a second restimulation (Figure 1F).
Overall, these results show that delivery of LmSTI1a via anti-
DEC mAb is effective at inducing significantly higher frequencies
of antigen-specific CD4+ T cells producing elevated levels of three
Th1 cytokines in two different MHC II haplotypes, H-2b and H-
2d. These features, i.e., multifunctionality, high cytokine produc-
tion, and proliferation abilities, have been associated with
generation of protective T cell immunity to cutaneous leishman-
iasis.
Dendritic Cell-Based Vaccine to Leishmania major
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67453
Figure 1. Single dose of anti-DEC-LmSTI1a immunizes multifunctional Th1 CD4+ T cells in vivo. (A) C57BL/6 mice were intraperitoneally
inoculated with 1 mg of anti-DEC-LmSTI1a or control Ig-LmSTI1a plus 50 mg poly ICLC and 25 mg anti-CD40 mAb (Adjuvants, Adj). Fourteen days later,
splenocytes were restimulated in vitro with LmSTI1a reactive peptide mix or LeIF nonreactive peptide mix in the presence of BFA. Intracellular
cytokine staining was performed to detect IFN-c in CD3+ CD4+ T cells. (B) As in A, but % of IFN-c+CD4+ T cells is shown as mean 6 SEM (n = 9). (C) Top
panel shows the gating strategy to identify multifunctional T cells using multiparameter flow cytometry. CD3+ CD4+ IFN-c+T cells (middle FACS plot)
were analyzed for production of IL-2 and TNF-a (right FACS plot). Bottom bar graph shows the frequencies of total CD4+ T cells expressing each of the
four cytokine combinations. Graph is expressed as the frequency of CD4+ CD3+ T cells and the mean 6 SEM (n = 9). (D) IFN-c median fluorescence
intensity (MFI) of antigen-specific CD4+ T cells producing three, two, or one cytokines (IFN-c alone or with TNF-a and/or IL-2) following immunization
of C57BL/6 mice as in A. (E) As in A, but in Balb/c mice. The % of CD4+ T cells is shown as the mean 6 SEM (n = 10). (F) As in E, but bulk splenocytes
were CFSE-labeled and stimulated with LmSTI1a reactive peptide mix or LeIF nonreactive peptide mix for 4 days, wherein the cells were restimulated
with LmSTI1a reactive peptide mix in the presence of BFA to detect IFN-c+ cells in proliferating CFSElow CD3+ CD4+ T cells. The frequency of CFSElow
IFN-c+ CD4+ T cells is shown as the mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0067453.g001
Dendritic Cell-Based Vaccine to Leishmania major
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Targeting LmSTI1a to DCs via anti-DEC mAb is more
Efficient than Non-targeted LmSTI1a Protein for
Induction of Th1 CD4+ T cell Responses
To evaluate the role of DCs in immunization, C57BL/6 mice
were inoculated with graded doses of anti-DEC-LmSTI1a mAbs,
control Ig-LmSTI1a mAb, or non-targeted LmSTI1a protein in
the presence of the adjuvant. Anti-DEC-LmSTI1a was more
efficient than control Ig-LmSTI1a at priming IFN-c-producing
CD4+ T cells and elicited significantly greater T cell responses
than equivalent amounts of non-targeted protein (Figure 2A).
We further confirmed that these responses were receptor
mediated. As shown in Figure 2B, T cell responses induced by
anti-DEC-LmSTI1a in DEC-deficient mice were reduced approx-
imately 10-fold (Figure 2B). Thus, DEC-mediated delivery of
LmSTI1a antigen to DCs in vivo results in antigen-specific CD4+ T
cell responses that are dependent on the presence of the DEC
receptor.
CD4+ T cell Responses Induced by anti-DEC-LmSTI1a are
Directed to Several LmSTI1a Epitopes
The breadth of antigen-specific T cell responses is reflected by
the diversity of reactive epitopes recognized by T cells on distinct
MHC class II haplotypes. To assess the breadth of the Th1
response and identify the individual LmSTI1a epitopes recognized
by antigen-specific CD4+ T cells following immunization with
anti-DEC-LmSTI1a mAb, we used a peptide library of 15-mer
‘‘mimetopes’’ staggered by 4aa along the 1–398 aa sequence of
LmSTI1a. The library was divided into 10 sequential peptide
pools, each containing 12 peptides. Each pool was used to
restimulate splenocytes from mice immunized with anti-DEC-
LmSTI1a mAb, and IFN-c production was evaluated by FACS.
As shown in Figure 3, CD4+ T cells from Balb/c and C57BL/6
mice responded to at least two different peptide pools, pool 2 and
8, whereas C57BL/6 mice also responded to peptide(s) in pool 1
(Figure 3, A and B). The aa sequences covered by LmSTI1a
peptide pools 1, 2, and 8 are shown in Table S1.
We then identified individual reactive peptides in the H-2d
haplotype. Each peptide within pools 2 and 8 was used to
restimulate splenocytes from Balb/c mice immunized with anti-
DEC-LmSTI1a (Figure S4A). We found that the CD4+ T cell
responses in Balb/c mice were directed to two overlapping
peptides from each pool, i.e., peptides 16–17 in pool 2 and 87–88
in pool 8 (Figure S4A and Table 1). The sequences within these
peptides cover two epitopes previously described in the H-2d
haplotype (Figure S4A, underlined aa sequences) [37]).
To identify individual reactive CD4 epitopes in the H-2b
haplotype, which have not been reported previously, C57BL/6
splenocytes of mice immunized with anti-DEC-LmSTI1a were
restimulated with single peptides from pools 1, 2, and 8 (Figure
S4B). Six peptides (two overlapping peptides from each pool) were
able to induce IFN-c production by CD4+ T cells from anti-DEC-
LmSTI1a immunized mice (Figure S4B and Table 1). The
dominant epitope was located within aa 348–366 (VEEAYID-
PEIAKQKKDEGN) of the LmSTI1 sequence (Table 1).
Since the CD4+ T cell responses were mainly directed to three
immunodominant overlapping peptides localized in pool 8,
peptides 87, 88, and 89, we genetically engineered their peptide
sequence into the C-terminal domain of the heavy chain of anti-
DEC mAb (anti-DEC-LmsTI1344–366; Figure S2). Balb/c mice
were immunized with anti-DEC-LmsTI1344–366 plus adjuvant,
and 14 days later, we evaluated IFN-c-producing CD4+ T cells by
FACS. Inoculation of 1 mg of anti-DEC-LmSTI1344–366 mAb
generated around two times more IFN-c-producing CD4+ T cells
than 10 mg of non-targeted LmSTI1344–366 peptide, suggesting
that peptide targeting to DCs was approximately 20 times more
efficient (Figure 3C). The frequency of CD4+ T cells producing
IFN-c after immunization with anti-DEC-LmSTI1344–366 was
slightly lower than, but not significantly different from, animals
immunized with anti-DEC-LmSTI1a mAbs (Figure 3C).
Thus, a single inoculation of LmSTI1a targeted to DCs using
anti-DEC mAb results in broad CD4+ T cell responses directed to
at least two different peptides in H-2d and H-2b backgrounds,
including a dominant epitope localized within aa 344–366. In
Figure 2. Priming of Th1 CD4+ T cells with anti-DEC-LmSTI1a in vivo requires targeting to DEC+ DCs. (A) C57BL/6 mice were
intraperitoneally immunized with different doses of anti-DEC-LmSTI1a, control Ig-LmSTI1a, or non-targeted LmSTI1a protein (0.1–10 mg) in the
presence of 50 mg poly ICLC and 25 mg anti-CD40 (Adj). Fourteen days after immunization, splenocytes were restimulated in vitro with a reactive
LmSTI1a peptide mix for 6 h in the presence of BFA. Intracellular staining was performed to detect IFN-c production in CD3+ CD4+ T cells. The mean
6 SEM (n = 6). (B) As in A, but C57BL/6 wild-type or DEC2/2 mice were immunized with 10 or 1 mg of anti-DEC-LmSTI1a mAb plus Adj. Plots are
representative of two experiments.
doi:10.1371/journal.pone.0067453.g002
Dendritic Cell-Based Vaccine to Leishmania major
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Figure 3. CD4+ T cell responses induced by anti-DEC-LmSTI1a are directed to several epitopes. (A) Balb/c or C57BL/6 mice were
intraperitoneally immunized with 1 mg of anti-DEC-LmSTI1a plus poly ICLC (50 mg) and anti-CD40 mAb (25 mg) (Adj). Fourteen days later, splenocytes
were restimulated with 10 different LmSTI1a peptide pools (2 mg/ml), each containing 12 individual peptides. IFN-c-producing CD4+ T cells were
assessed by intracellular cytokine staining. (B) As in A, but the percentage of IFN-c+ CD4+ T cells is shown as mean 6 SEM (n = 6). (C) Balb/c mice were
immunized with 1 mg of anti-DEC-LmSTI1a or anti-DEC-LmSTI1344–366 mAbs or 10 mg of non-targeted LmSTI1348–362 immunodominant peptide in the
presence of 50 mg poly ICLC and 25 mg anti-CD40 mAb (Adj). Production of IFN-c was evaluated by FACS after restimulation with LmSTI1a reactive
peptide mix or LeIF nonreactive peptide mix. The % of IFN-c+ CD4+ T cells is shown as mean 6 SEM (n = 3).
doi:10.1371/journal.pone.0067453.g003
Dendritic Cell-Based Vaccine to Leishmania major
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addition, when the immunodominant LmSTI344–366 peptide is
delivered using anti-DEC mAb, the efficiency of targeting is
preserved.
LmSTI1 is a Superior Antigen for Induction of Th1
Responses
Identification of protective antigens is a major goal for
generation of new and improved vaccines against L. major.
Accordingly, we compared LmSTI1a with other previously
described antigens of Leishmania spp., LACK and LeIF, for their
capacity to induce IFN-c-producing CD4+ T cells and protect
against subsequent challenge with L. major.
Since the immunomodulatory properties of LeIF are localized
in the N-terminal domain (aa 1–226) [38], we genetically
engineered anti-DEC mAb to express LeIF1–226 (Figure S2, F–I).
We also used for comparison anti-DEC-LACK mAb [20], and the
C-terminus domain of the LmSTI1 gene (anti-DEC-LmSTI1b,
Figure S2, A–E).
Balb/c mice were immunized with anti-DEC mAb coupled with
LmSTI1a, LmSTI1b, LACK, or LeIF along with the adjuvant,
and antigen-specific responses were evaluated by detection of IFN-
c-producing CD4+ T cells. As shown in Figure 4, anti-DEC-
LmSTI1a and anti-DEC-LmSTI1b induced the highest frequen-
cies of IFN-c+ CD4+ T cells compared with anti-DEC-LACK or
LeIF. Epitope analysis revealed that the response to LACK was
directed to a single, previously described epitope, corresponding to
aa 156–173 (Table 2) [39]. The CD4+ T cell response to LeIF in
Balb/c mice was also directed to a single, uncharacterized epitope
localized in our pool 5 within aa 141–162 (Figure S4C and
Table 2).
In contrast to targeting LACK or LeIF, delivery of LmSTI1b
using anti-DEC mAb induced higher frequencies of CD4+ IFN-c+
T cells than delivery of LmSTI1a (Figure 4). However, LmSTI1b-
specific CD4+ T cell responses were directed to a single, previously
described epitope [37] localized in our pools 9–10 (Figure S4D),
within aa 422–444 (Table 2). Moreover, LmsTI1b, as well as
LACK and LeIF, induced CD4+ T cell responses only in Balb/c
mice and not in C57BL/6 mice (data not shown). Overall, we
concluded that LmSTI1a has several advantages compared with
other L. major antigens, including potent generation of Th1 T cell
responses directed to at least two epitopes in two different
haplotypes, i.e., H-2b and H-2d.
Targeting LmSTI1a to DCs Using mAbs against DEC Elicits
Superior Protection against L. major Challenge
We next compared the protective potential of different
Leishmania antigens delivered to DCs within mAb against DEC.
To facilitate translation into the clinic, we inoculated fusion mAbs
subcutaneously, which is one of the most attractive ways for
vaccination in humans [40,41], in a prime-boost regimen using
poly ICLC as the adjuvant [24,25].
Susceptible Balb/c mice vaccinated with different antigens fused
to anti-DEC mAbs were challenged 10–15 days later with a low
dose of metacyclic promastigotes administered intradermally in
the ear pinnae. Lesion development and parasite burden was
evaluated in the challenged site and ear-draining lymph nodes
(LNs). Vaccination with anti-DEC-LmSTI1a mAb plus poly ICLC
resulted in approximately 100% protection (16 mice in four
independent experiments), i.e., reduced pinnae edema and
necrosis. In contrast, anti-DEC-LeIF mAb resulted in approxi-
mately 30–40% protection (six of 16 mice in four different
experiments), while anti-DEC-LACK failed to induce protection
against L. major infection (Figure S5A). Skin lesions were correlated
with parasite numbers in the ear and ear-infected draining LNs
(Figure 5, A and B). Mice vaccinated with anti-DEC-LmSTI1a
mAb showed significantly lower number of parasites at the ear-
infected draining LN (Figure 5A) compared with control-Ig
LmSTIa and almost no parasites in the ear pinnae (Figure 5B).
Vaccination with anti-DEC-LeIF mAb also exhibited moderate
reduction in the size of the lesions, which correlated with a lower
number of parasites in the LN and ear pinnea than that in PBS-
treated animals, but was not as potent as treatment with anti-
DEC-LmSTI1a (Figure 5, A and B). On the other hand, mice
treated with anti-DEC-LACK or control Ig-LmSTIa mAbs
showed the highest number of parasites in the infection site and
the ear-infected draining LN (Figure 5, A and B).
The protective effect of anti-DEC-LmSTI1a mAb was also
observed when Balb/c mice were challenged with a high dose of
metacyclic promastigotes administered subcutaneously in the
footpad (Figure S5B). Again, anti-DEC-LmSTI1a mAbs conferred
complete protection (100% of the animals) with negligible footpad
swelling and undetectable parasites in the lesions, whereas anti-
DEC-LeIF and anti-DEC-LmSTI1b resulted in partial protection
(40% and 80% of the animals, respectively; Figure S5B and C).
We further evaluated the protective effect of anti-DEC-
LmSTI1a in the innately resistant mouse strain C57BL/6. As
shown in Figure S5D, vaccination of C57BL/6 mice with anti-







15-mer peptide Position (aa) Sequence %IFN-c+ CD4+ T cells
C57Bl/6 H-2b 1 p5 17–31 GRYVEAVNYFSKAIQ 0.52660.159
p6 21–35 EAVNYFSKAIQLDEQ 0.26660.120
C57Bl/6 H-2b 2 p16 61–75 DKCISIKPNWAKGYV 0.31560.198
p17 65–79 SIKPNWAKGYVRRGA 0.23660.146
C57Bl/6 H-2b 8 p88 348–362 VEEAYIDPEIAKQKK 3.05260.982
p89 352–366 YIDPEIAKQKKDEGN 2.33560.776
Balb/c H-2d 2 p16 61–75 DKCISIKPNWAKGYV 0.39060.103
p17 65–79 SIKPNWAKGYVRRGA 0.21560.035
Balb/c H-2d 8 p87 344–358 HQKAVEEAYIDPEIA 0.80560.173
p88 348–362 VEEAYIDPEIAKQKK 1.01260.366
doi:10.1371/journal.pone.0067453.t001
Dendritic Cell-Based Vaccine to Leishmania major
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67453
DEC-LmSTI1a mAb plus poly ICLC could confer some degree of
protection against a low dose of metacyclic promastigotes
administered intradermally represented by the reduced number
of parasites detected in the infection site.
Finally, we evaluated the ability of anti-DEC-LmSTI1a to
confer long-term protection against infection. Balb/c mice
immunized with anti-DEC-LmSTI1a mAb plus adjuvant were
challenged with live metacyclic promastigotes 12 weeks after the
last immunization. Only immunization with anti-DEC-LmSTI1a,
but not a control Ig-LmSTI1a mAb, could confer durable
protection (100% of the animals), which correlated with a low
number of parasites in the ears and ear-infected draining LN
(Figure 5C, data now shown).
To examine the nature of the protection induced by anti-DEC-
LmSTI1a mAb, we analyzed IFN-c, IL-4, and IL-10 responses 12
weeks after challenge with L. major. Lymphocytes from ear-infected
draining LN from mice immunized with anti-DEC-LmSTI1a
produced significantly less IL-4 in response to stimulation ex vivo
with soluble Leishmania antigen (SLA) but comparable levels of
IFN-c compared with mice inoculated with control Ig-LmSTI1
(Figure S6, A and B). Consequently, the IFN-c/IL-4 ratios in mice
vaccinated with anti-DEC-LmSTI1a were highest compared with
control Ig-LmSTI1, anti-DEC-LeIF, or anti-DEC-LACK
(Figure 6A). Similarly, lymphocytes from mice vaccinated with
anti-DEC-LmSTI1a produced significantly less IL-10 after stim-
ulation ex vivo with SLA (Figure 6B). Taken together, these results
suggest that the superior protection in anti-DEC-LmSTI1a
vaccinated mice can be explained, at least in part, by a shift
toward a Th1 phenotype.
Overall, we concluded that LmSTI1 targeted to DCs via DEC
mAbs is the most effective L. major antigen to prevent cutaneous
leishmaniasis.
Discussion
Given the lack of effective and low-cost treatment, several
strategies are being evaluated as potential vaccine candidates
against leishmaniasis [7,8,9,10,11]; however, there are still no
licensed vaccines [42]. Considering their unique capacity to induce
and regulate immune responses, DCs offer a promising approach
for development of novel vaccines. It has been previously shown
that adoptive transfer of DCs loaded ex vivo with parasite antigens
can mediate protection against Leishmania infection [7,19,43].
However, this approach relies on laborious and expensive isolation
Figure 4. LmSTI1 targeted within anti-DEC mAbs induces superior Th1 immunity compared with other L. major antigens. Balb/c mice
were intraperitoneally immunized with 10 mg of anti-DEC mAbs fused with LACK, LeIF, LmSTI1a, or LmSTI1b in the presence of 50 mg poly ICLC and
25 mg anti-CD40 mAb (Adj). Fourteen days after the immunization, splenocytes were restimulated in vitro with 2 mg of LACK, LeIF, or LmSTI1 peptide
mix or medium alone (negative control) in the presence of BFA for 6 h. Intracellular cytokine staining was performed to detect IFN-c+ cells on CD3+
CD4+ T cells. Data is shown as the mean 6 SEM (n = 4–8).
doi:10.1371/journal.pone.0067453.g004
Table 2. Identification of LACK-, LeIF-, and LmSTI1b-specific CD4+ T cell responding peptides in Balb/c mice.
L. major antigen Reactive peptide pool Responding 15-mer peptide Position (aa) Sequence
LACK 1 p7–p8 156–173 ICFSPSLEHPIVVSGSWD1
LeIF 5 p43–p45 141–162 LRKLQAGVIVAVGTPGRVSDVI
LmSTI1b 9–10 p107–p109 422–444 KPDFVKGYARKGHAYFWTKQYNR2
1The sequence of the previously described reactive epitope in Balb/c mice is underlined [39].
2The sequence of the previously described reactive epitope in Balb/c mice is underlined [37].
doi:10.1371/journal.pone.0067453.t002
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and ex vivo culture of cells. A novel approach is targeting antigens
to DCs in situ in the intact animal using mAbs against DEC.
Despite previous success using this DC-targeting approach for
induction of protective immune responses against viruses [22],
bacteria [27,28], and even tumor cells [44,45], to the best of our
knowledge, this is the first report evaluating the efficacy of this
strategy for generation of protective immune responses against a
protozoan parasite. The findings in this report show that delivery
of LmSTI1 to adjuvant-matured DCs was sufficient to induce
protective immunity to L. major, one of the causative agents of
human cutaneous leishmaniasis.
We chose LmSTI1 based on several criteria. STI1 is a protein
highly conserved among different Leishmania species, suggesting
that in addition to being useful for L. major infection, an anti-DEC-
LmSTI1a vaccine may be useful for other forms of leishmaniasis,
including visceral and mucosal leishmaniasis. LmSTI1 is present in
the amastigote and promastigote form of the parasite [29].
Furthermore, LmSTI1 is divergent from its mammalian protein
counterpart, indicating a decreased risk for undesirable patholog-
ical crossactivation of autoreactive T and B cells. Importantly,
immunization with recombinant LmSTI1 protein administered
alone or as a poly protein fused with other parasite proteins
induces protection in susceptible Balb/c mice [32,33,46]. Our
results demonstrate that anti-DEC-LmSTI1a induces several fold
greater responses than LmSTI1 protein alone and confers a high
level of protection against challenge with L. major in susceptible
Balb/c and resistant C57BL/6 mice. Protection against L. major
infection was consistent, even at low doses (1 mg) of fusion mAbs,
and was durable for at least 12 weeks after immunization. In
addition, anti-DEC-LmSTI1a protection was achieved despite
increasing the parasite load (200–16106), or varying the site of
infection (intradermal and subcutaneous).
Protection against Leishmania in experimental mouse models is
thought to be primarily mediated by the production of IFN-c [3].
The main source of IFN-c is antigen-specific CD4+ T cells [47].
Furthermore, it was recently shown that vaccine-induced protec-
tion against L. major strongly correlates with generation of
multifunctional Th1 CD4+ T cells producing high levels of IFN-
c, IL-2, and TNF-a [35]. Therefore, protection against infection
seems to be dependent not only on the magnitude but also on the
Figure 5. Anti-DEC-LmSTI1a mAb elicits protection against L. major. Balb/c mice were vaccinated in a prime-boost regimen consisting of two
subcutaneous doses, administered 1 month apart, with 10 mg or 1 mg of control Ig-LmSTI1a or anti-DEC-LmSTI1a and 10 mg of anti-DEC-LACK or anti-
DEC-LeIF mAbs in the presence of 50 mg poly ICLC. Ten to 15 days after boost, the mice were intradermally injected in the ear pinnae with 200–1000
L. major metacyclic promastigotes. Quantification of parasites obtained from ear-infected draining LN (A) or per infected ears (B) were calculated 12
weeks after challenge. Shown is the mean 6 SEM (n = 5–12, except PBS, n = 2). (C) As in B, but Balb/c mice were intradermally challenged with 200–
1000 L. major metacyclic promastigotes 12 weeks after the last immunization. Shown is the mean 6 SEM (n = 5, except PBS, n = 3).
doi:10.1371/journal.pone.0067453.g005
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quality of the CD4+ T cell response generated. Accordingly,
delivery of LmSTI1a to DCs via DEC mAbs in combination with
a DC maturation stimulus induced potent multifunctional (IFN-
c+/IL-2+/TNF-a+) antigen-specific CD4+ T cells. Additionally,
vaccine-induced LmSTI1a-specific CD4+ T cells proliferated
vigorously and secreted high amounts of IFN-c upon antigen
restimulation in vitro.
The quality of the CD4+ T cell response induced by anti-DEC-
LmSTI1a mAbs was also reflected by its breadth, i.e., T cell
responses were produced in two different MHC haplotypes (H-2b
and H-2d), and the response was directed to at least two peptides in
each haplotype. The peptides recognized following anti-DEC-
LmSTI1a immunization in Balb/c mice were identical to those
reported previously in H-2d [37]. We extended the analysis to
identify peptides recognized by CD4+ T cells in C57BL/6 (H-2b),
which had not been assessed previously. Interestingly, the CD4+ T
cell response was mainly directed to a dominant peptide, similar in
sequence to the one recognized in Balb/c mice. Consequently, we
delivered the LmSTI1344–366 peptide to DCs using anti-DEC
mAbs, and as expected, this strategy also immunizes CD4+ T cells.
We further compared other L. major proteins as vaccine
candidates by DEC targeting to DCs. LACK is another well-
conserved Leishmania antigen; however, previous reports indicate
that LACK fails to elicit long-term protective immune responses
against L. major or other Leishmania species [48,49]. Despite the
ability of anti-DEC-LACK mAbs to prime some IFN-c+ CD4+ T
cells in agreement with a previous report [20], LACK targeting
did not confer any protection against a low-dose L. major challenge
in susceptible Balb/c mice, suggesting that this antigen is not
adequate for traditional and/or DC-targeting immunization
approaches.
On the other hand, LeIF antigen can expand antigen-specific
Th1 cells [38,50], and in our DEC DC-targeting model, it induced
detectable levels of antigen-specific IFN-c-producing CD4+ T
cells. Distinct from LmSTI1a, responses induced by LeIF were
restricted to H-2d, as shown by the lack of CD4+ T cell induction
in C57BL/6 mice. Immunization of Balb/c mice with anti-DEC-
LeIF induced partial protection (30–40%) following challenge with
L. major. This could be related to the fact that the CD4+ T cell
response with anti-DEC-LeIF was directed to only one epitope
and induced lower frequencies of IFN-c+ CD4+ T cells compared
with LmSTI1a.
Given that the entire LmSTI1 protein could not be coupled to
anti-DEC mAb, we performed a partial comparison of the N-
terminal (LmSTI1a) and C-terminal (LmSTI1b) portions. Com-
pared with LmSTI1a, LmSTI1b-specific CD4+ T cell responses
were restricted to H-2d and were directed to a single immuno-
dominant epitope. Nevertheless, anti-DEC-LmSTI1b mAb in-
duced high frequencies of IFN-c+ CD4+ T cells and protective
responses to a high-dose subcutaneous challenge with L. major. In
the future, it will be interesting to study the effectiveness of a DC-
based vaccine that includes more than one Leishmania antigen, e.g.,
LmSTI1a, LmSTI1b, and LeIF. Such a vaccine, Leish-111f
[32,51], is currently being studied with protective responses;
however, it would be interesting to see if its efficacy is increased by
DC targeting.
Despite the antigen being targeted, we found that protection
against L. major infection was associated with a significant
difference in the IFN-c/IL-4 cytokine ratio, driven mainly by
the decreased secretion of IL-4 in protected mice. Interestingly, we
also found a decrease in the secretion of IL-10 in anti-DEC-
LmSTI1a vaccinated mice. These results suggest that although
additional, unexplored mechanisms may be involved, a Th1-
biased response is correlated with protective immunity.
Efficient induction of CD4+ T cell responses in our model was
dependent on the expression of the DEC receptor, as shown in
DEC-deficient mice. In mice, DEC is expressed by a subset of DCs
coexpressing CD8a that is able to produce high levels of IL-12 in
response to microbial signals [52,53]. This ability to produce IL-12
is critical for generation of Th1 responses. Indeed, targeting
CD8aa+ DCs, but not CD8aa2 DCs, leads to a large polarized
antigen-specific Th1 response [20,24]. Furthermore, skin migra-
tory DC subsets, including Langerhans cells and dermal DCs,
express high levels of DEC and may be involved in generation of
protective Th1-dependent immunity via IL-12 [3]. Further studies
are needed to investigate the role of distinct DCs subsets in
generation of protective Th1 T cell responses after targeting of
leishmania antigens to DEC+ DCs.
Priming of Th1 CD4+ T cell responses using anti-DEC mAb
requires maturation of DCs with TLR agonists. In this study, we
Figure 6. Analysis of the cytokine responses after challenge with L. major. As in Figure 5, but 12 weeks after infection with L. major, total cell
suspensions of ear-infected draining LN were restimulated in vitro for 72 h with 10 mg/ml of SLA. The levels of IFN-c, IL-4, and IL-10 cytokines in the
culture supernatants were determined by ELISA. Data is shown as the mean 6 SEM of the ratio of (A) IFN-c/IL-4 and (B) IL-10 (n = 4–10).
doi:10.1371/journal.pone.0067453.g006
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selected poly ICLC, a microbial mimic TLR-3 and MDA5
agonist, because of its capacity to promote strong Th1 responses
[24,25,26] and its superiority compared with other adjuvants, e.g.,
GLA-SE [54]. Importantly, poly ICLC is safe and well tolerated in
humans [55].
Preventive vaccines are considered the best and most cost-
effective approaches against pathogens, including Leishmania. Here
we demonstrate how DCs can be exploited to prevent infection
induced by the human intracellular pathogen L. major. As we learn
more about DCs, we can decide about different targeting
strategies. For example, we can direct antigens to distinct subsets
of DCs in vivo using mAbs against uptake receptors differentially
expressed by DC populations. In this regard, it would be
interesting to evaluate targeting of Leishmania antigens to
CD207/Langerin+ DC, including Langerhans cells, which are
one of the parasite’s targets [56]. Furthermore, Leishmania antigens
can be delivered to macrophages, the cell type most infected by the
parasite [57], using mAbs against Treml4 [45].
Taken together, our results show that delivery of LmSTI1a to
adjuvant-matured DCs significantly enhances antiparasite immu-
nity. This strategy would seem logical to pursue clinically as a
feasible approach for Leishmania infections.
Materials and Methods
Mice
We purchased female Balb/cJ and C57BL/6J mice from The
Jackson Laboratory. DEC2/2 mice were kindly provided by M.
Nussenzweig (The Rockefeller University, New York, NY) and
bred in house. The mice were maintained under specific
pathogen-free conditions and used at 6–8 weeks of age.
Ethics Statement
This study was conducted in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
Animal Care and Use Committee at The Rockefeller University
(Protocol Number: 11414). All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made to
minimize suffering.
Reagents
The following fluorescent conjugated mAbs were purchased
from eBioscience (San Diego, CA) or BD Biosciences (Franklin
Lakes, NJ): Alexa-488 anti-IL-2 (JES6-5H4), eFluor-450 or Alexa-
700 anti-CD3 (500A2), Alexa-700 or PE anti-CD4 (RM4-5), APC
or PE-Cy7 anti-IFN-c (XMG1.2), and PE-Cy7 anti-TNF-a MP6-
XT22). Other reagents were live/dead fixable aqua or violet
vitality dye from Life Technologies (Grand Island, NY), and CFSE
(5,6-carboxyfluorescein diacetate succinimidyl ester, Life Tech-
nologies). Overlapping (staggered by four amino acids) 15-mer
peptides covering the LmSTI1, LeIF, or LACK sequences were
synthesized by H. Zebroski in the Proteomics Resource Center of
The Rockefeller University.
Engineering and Production of Fusion mAbs and
LmsTI1a Soluble Protein
Open reading frames were amplified by PCR from genomic
DNA generously provided by Dr. Nicholas Glaichenhaus (Friedlin
strain of L. major), with the sets of primers described in Table S2.
DNA coding for LmSTI1344–366 peptide was generated by the
annealing of complementary synthetic oligonucleotides (Table S2).
The PCR products were inserted in frame to the C-terminus of the
heavy chain of anti-mouse-DEC (NLDC; [58,59,60]), and a
control Ig mAb with no receptor affinity (GL117; [60]). The fusion
mAbs were expressed by transient transfection using calcium
phosphate in 293T cells in the presence of serum-free DMEM
medium supplemented with Nutridoma SP (Roche Applied
Science, Indianapolis, In). The mAbs were purified on protein G
columns (GE Healthcare Biosciences, Pittsburg, PA) and charac-
terized by SDS-PAGE and Western blotting using anti-mouse-
IgG1-HRP (Southern Biotech, Birmingham, AL). Binding of the
produced mAb to the cognate receptor was verified by FACS on
CHO cells stably transfected with mouse DEC, using PE-
conjugated goat anti-mouse-IgG (Jackson ImmunoResearch, West
Grove, PA). For expression of soluble LmSTI1a protein, the DNA
encoding the first 1194 nucleotides of the LmSTI1 gene was
amplified by PCR using primers described in Table S2. The PCR
products were digested with BamHI and NotI, gel purified, and
ligated in frame into the pET28b-SMT3 vector (generous gift from
Dr. E. Mossessova, Memorial Sloan-Kettering Cancer Center)
[61], followed by transformation into BL21 Escherichia coli (Life
Technologies). Soluble protein was purified by nickel–agarose
chromatography (Qiagen, Valencia, CA), followed by removal of
His10-Smt3 with protease Ulp1, as described previously [61]. The
concentration of all proteins produced, i.e., soluble protein and
mAbs, was determined using the DC protein assay kit (BioRad,
Hercules, CA). All proteins were examined for the presence of
endotoxin using the Limulus amebocyte lysate assay, QCL-1000
(Cambrex, Walkersville, MD), and if necessary, removed using
Triton-X, as described previously [62].
Parasite Growth and Preparation of SLA
L. major (Friedlin strain, generously provided by Frederick S.
Buckner, University of Washington) promastigotes were cultured
at 27uC in M199 medium (Life Technologies) supplemented with
20% heat-inactivated FCS (Life Technologies), 0.5% penicillin/
streptomycin (Life Technologies), 0.1 mM adenine (in 1 N
NaOH), and 5 mg/ml hemin (in 50% triethanolamine) (both from
Sigma) (Complete M199). In all experiments, promastigotes were
used after one to three passages in vitro. Infective-stage metacyclic
promastigotes were isolated from stationary cultures (4–5 days old)
by negative selection of noninfective forms using peanut agglutinin
(PNA, Vector Laboratories, Inc., Burlingame, CA. [63]). SLA was
prepared from log-phase promastigotes (approximately 108
parasites/ml), washed three times in PBS, and lyzed by seven
cycles of freezing and thawing. Protein concentration was assessed
by the BCA protein assay kit (Thermo Scientific, Rockford, Il).
Mice Immunization and in vivo Challenge with L. major
The mice were immunized intraperitoneally one time with
fusion mAbs in the presence of a stimulus for DC maturation,
which was 50 mg poly ICLC (Oncovir, Washington, DC) together
with 25 mg IC10 agonistic anti-CD40 mAb (produced in house).
For parasite challenge experiments, anti-CD40 was omitted and
the mice were inoculated subcutaneously in the footpad (50 ml per
pad) in a prime-boost regimen consisting of two doses of 1–10 mg
of fusion mAbs in the presence of 50 mg poly ICLC administered 1
month apart. Two to twelve weeks after the last vaccination, the
animals were completely anesthetized with 1–1.5 mg Nembutal
sodium (OVATION Pharmaceuticals, Inc.) and challenged with L.
major stationary-phase metacyclic parasites. For high-dose chal-
lenge experiments, the mice were subcutaneously infected with
16106 parasites in the contralateral footpad to the vaccination site,
and disease progression was monitored by measurement of
footpad swelling with a caliper. In the low-dose challenge
experiments, the mice were intradermally infected with 200–
1000 parasites (in 20 ml) in the ear pinna. The animals were
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sacrificed when signs of footpad or ear ulceration became apparent
at approximately 8–14 weeks after infection.
Estimation of Parasite Loads
The amount of viable parasites in the infected ear, footpad, and
draining LN were determined by a limiting dilution assay, as
described previously [64]. In brief, infected ears and footpads were
collected, weighed, and homogenized individually in 5 ml of
complete M199. Single-cell suspensions were prepared from ear-
infected draining LN in complete M199 and adjusted to equal cell
numbers and volumes. In all cases, 10-fold serial dilutions were
performed, and for each dilution, 12 replicates were plated on 96-
well round-bottom plates, which were incubated for 10–15 days at
27uC in a CO2-free incubator. The number of parasites was
estimated by multiplying the reciprocal of the last dilution showing
at least one positive well with the initial dilution factor. Parasite
loads were expressed as the number of L. major parasites per
homogenized infected ear or footpad or per total cells in the
draining LN.
Intracellular Cytokine Staining and in vitro Proliferation
Assay
Spleens were force-passed through a 70-mm cell strainer to
obtain a homogeneous cell suspension in RPMI 1640 medium
(Life Technologies) complemented with 10% FBS, 10 U/ml
penicillin/streptomycin (Life Technologies), 200 mM/ml gluta-
mine (Life Technologies), and 50 mM 2-mercaptoethanol (Sigma-
Aldrich, St. Louis, MO). Red blood cells were lysed by incubating
with RBC lysis buffer (BioWhittaker, Walkersville, MD) for 1 min.
Bulk splenocytes were restimulated with 15-mer peptide mix from
LmSTI1 (2 mg/ml) or nonreactive LeIF (2 mg/ml) in the presence
of 2 mg/ml of costimulatory anti-CD28 (clone 37.51, ATCC
produced in house) for 6 h at 37uC, adding 10 mg/ml Brefeldin A
(BFA; 10 mg/ml, Sigma-Aldrich) for the last 5 h of incubation in
order to allow accumulation of intracellular cytokines. In some
experiments, the splenocytes were labelled with CFSE to evaluate
the proliferative capacity of primed T cells [22,24]. In brief, bulk
splenocytes (16107 cells/ml) were labeled with 2.5 mM CFSE at
37uC for 10 min. CFSE-labeled T cells were then restimulated
with 15-mer peptide mix from LmSTI1 (0.2 mg/ml) or nonreactive
LeIF (0.2 mg/ml) for 4 days, followed by restimulation with 2 mg/
ml reactive peptide mix for another 6 h in the presence of BFA for
evaluation of intracellular cytokines. The cells were washed,
incubated for 10 min at 4uC with anti-CD16/32 mAb (2.4G2,
produced in house) to block Fcc receptors, and stained with mAbs
against surface molecules for 20 min at 4uC. The cells were then
fixed, permeabilized (Cytofix/Cytoperm; BD Biosciences), and
stained with mAbs against cytokines. 1–36105 live CD3+ cells
were acquired on a BD LSR II Flow cytometer (BD Biosciences),
and data were analyzed with FlowJo Software (TreeStar, San
Carlos, CA).
Cytokine ELISAs
Single-cell suspensions were prepared from ear-infected drain-
ing LN. 56105 cells/well (96-well round-bottom plates) were
plated in the presence of 10 mg/ml SLA. Seventy-two hours later,
the culture supernatant was harvested and IFN-cIL-4, and IL-10
production was evaluated by ELISA (eBioscience), following the
manufacturer’s instructions.
Statistical Analysis
Data were analyzed and charts were generated using Prism 5
GraphPad software (San Diego, CA). Comparisons between two
groups were performed by unpaired Student’s t-test. Comparisons
between three or more groups were performed by one-way
ANOVA analysis (multiple comparisons Tukey’s post hoc test). P
values #0.05 were considered statistically different and labeled
with a single asterisk (*), in contrast to P values of #0.01 (**) or
#0.001 (***).
Supporting Information
Figure S1 STI1 aa sequence alignment from L. major,
L. infantum, L. donovani, and L. braziliensis. Amino acid
sequences were predicted from cDNA sequences obtained from
NCBI database (www.ncbi.nlm.nih.gov). Residues matching
between different Leishmania species are shown in dark gray boxes.
(TIF)
Figure S2 Quality control of anti-DEC mAb engineering
to expressed distinct L. major antigens. (A) STI1 from L.
major was divided into two fragments: the N-terminal portion (aa
1–398, red, LmSTI1a) and the C-terminal portion (aa 401–546,
blue, LmSTI1b). Each fragment was cloned in frame into the C-
terminal domain of the heavy chain of anti-DEC mAb or a control
Ig mAb without receptor affinity (represented in B, left diagram).
Furthermore, a small peptide (aa 344–366, pink) was cloned in
frame to the C-terminal domain of anti-DEC mAb after a short
linker (represented in B, right diagram). (B) Diagrammatic
representation of anti-DEC mAb conjugated with LmSTI1a and
LmSTI1b (left diagram) or with LmSTI1344–366 (right diagram).
(C) Coomassie blue-stained 10% (vol/vol) SDS-PAGE reducing
gel comparing fusion mAbs with the molecular mass in kDa. (D)
Western blotting of fusion mAbs using HRP-conjugated anti-
mouse IgG1. Molecular mass is indicated in kDa. (E) Binding of
the fusion mAbs to their cognate receptor analyzed by FACS.
CHO cells transfected to expressed mouse DEC (red) or control
non-transfected CHO cells (CHO-NEO, blue) were incubated
with graded doses (0.02–2 mg) of fusion mAb, followed by staining
with PE-labeled anti-mouse IgG. (F) The N-terminal portion of
LeIF (aa 1–226) was cloned in frame into the C-terminal domain
of anti-DEC mAb or a control Ig mAb. (G) Panel shows
Coomassie blue-stained SDS-PAGE as in C. (H) Panel shows
Western blotting as explained in D. (I) FACS plots show binding to
CHO cells expressing DEC as explained in E.
(TIF)
Figure S3 Multifunctional CD4+ T cell responses are
elicited by anti-DEC-LmSTI1a in Balb/c mice. Balb/c
mice were intraperitoneally immunized with 1 mg of anti-DEC-
LmSTI1a or control Ig-LmSTI1a mAbs in the presence of 50 mg
poly ICLC and 25 mg anti-CD40. Fourteen days later, splenocytes
were restimulated in vitro with a reactive LmSTI1a peptide mix in
the presence of BFA for 6 h. The production of IFN-c, TNF-a and
IL-2 was evaluated by FACS after intracellular cytokine staining,
and the frequencies of CD4+ IFN-c+ T cells also producing TNF-a
and/or IL-2 are shown as the mean 6 SEM (n = 6).
(TIF)
Figure S4 Identification of LmSTI1a-, LeIF-, and
LmSTI1b-CD4+ T cell epitopes in Balb/c and C57BL/6
mice. Balb/c (A) or C57BL/6 (B) mice were immunized with
anti-DEC-LmSTI1a mAb in the presence of 50 mg poly ICLC and
25 mg anti-CD40 mAb. Two weeks later, splenocytes were
restimulated with 2 mg/ml of the indicated individual LmSTI1a
peptide from pools 1, 2, and 8. IFN-c production was evaluated by
flow cytometry after intracellular cytokine staining, and the bars
are shown as the mean 6 SEM (n = 3). The aa sequence of the
reactive peptides is shown. The sequences of the previously
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described reactive epitopes in Balb/c mice are underlined [37]. (C)
Splenocytes from Balb/c mice immunized 14 days previously with
anti-DEC-LeIF mAb plus adjuvant were restimulated with 2 mg/
ml of the indicated individual peptides from pool 5. IFN-c
production was evaluated by flow cytometry after intracellular
cytokine staining. Bars are shown as the mean 6 SEM (n = 3), and
the aa sequence of the reactive peptide is shown. (D) As in C, but
animals were immunized with anti-DEC-LmSTI1b plus adjuvant.
The sequence of a previously described reactive epitope in Balb/c
mice is underlined [37].
(TIF)
Figure S5 Delivery of LmsTI1a to DCs using anti-DEC
mAbs protects mice against cutaneous leishmaniasis. (A)
Balb/c mice were primed and boosted 1 month apart with 10 mg
of anti-DEC mAbs coupled with LACK, LeIF, or LmSTI1a, or a
control Ig-LmSTI1a mAbs in the presence of 50 mg of poly ICLC.
Ten to 15 days after the last immunization, the mice were
challenged with a single dose of 200–1000 L. major metacyclic
promastigotes. Representative lesions in the ears of Balb/c mice 12
weeks after challenge are shown. (B) Balb/c mice were vaccinated
in a prime-boost regimen consisting of two doses of 10 mg of anti-
DEC or control Ig mAbs conjugated with either LmSTI1a,
LmSTIb, or LeIF, subcutaneously administered in the presence of
poly ICLC (50 mg) in the right footpad. Two weeks after the boost,
the mice were subcutaneously challenged in the left footpad with
1–26106 L. major metacyclic promastigotes. Vaccine efficacy was
determined by weekly measurement of the thickness of the infected
footpad. The mean 6 SEM is shown (n $4). (C) As in B, but the
number of parasites in the infected footpad is shown as the mean
6 SEM (n $4). n.d. = not detected. (D) As in A, but C57BL/6
mice were primed and boosted 1 month apart with two
subcutaneous doses of anti-DEC-LmSTI1a (1 mg) in the presence
of 50 mg of poly ICLC. Ten to 15 days after the last immunization,
mice were challenged with a single dose of 200–1000 L. major
metacyclic promastigotes. The quantification of parasites obtained
from the infected ears was determined 4 weeks after challenge.
The mean 6 SEM is shown (n = 4–5).
(TIF)
Figure S6 Cytokine profile from ear-infected draining
LN cells stimulated in vitro with SLA after intradermal
challenge with L. major. Total cell suspensions of ear-infected
draining LN obtained from mice immunized with different
preparations, as described in Figure 6, were restimulated in vitro
for 72 h with 10 mg/ml SLA. IL-4 (A) and IFN-c(B) levels in the
supernatants of the cultures were determined by ELISA. The
cultures were set in triplicates, and the data shows the mean 6
SEM (n $4).
(TIF)
Table S1 Peptide sequences covered by the immuno-
genic pools.
(DOC)
Table S2 Primers sequences.
(DOC)
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